Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

AstraZeneca reports positive results from Phase III trial of exenatide in type 2 diabetes British drug-maker AstraZeneca has reported positive results from a 28-week Phase III trial of exenatide to treat adult patients with type 2 diabetes. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

GSK reports positive results from Phase III BREAK-3 trial of tafinlar to treat melanoma
By PBR Staff Writer
GlaxoSmithKline (GSK) has reported updated results from a Phase III BREAK-3 trial of Tafinlar (dabrafenib) in patients with BRAF V600E mutant metastatic melanoma.
Contract Research & Services > Clinical Trials > News
Merck reports early data on investigational use of KEYTRUDA in patients with advanced bladder cancer
Merck, known as MSD outside the United States and Canada, has announced the first presentation of data on the investigational use of KEYTRUDA (pembrolizumab) – the company’s anti-PD-1 therapy – in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer).
Contract Research & Services > Clinical Trials > News

Contract Research

Cannabis Science signs drug development and laboratory services agreement with ImmunoClin
Cannabis Science a US Company specializing in cannabis formulation-based drug development and related consulting, has entered into a laboratory services agreement with ImmunoClin Corporation through its wholly-owned UK subsidiary, ImmunoClin, a healthcare company with over thirteen years' experience in providing premiere laboratory and related pre-clinical and clinical research services on a commercial scale.
Contract Research & Services > Contract Research > News
MedImmune, Cancer Research UK to establish joint laboratory for new biologic cancer medicines
By PBR Staff Writer
MedImmune, the global biologics research and development arm of AstraZeneca, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into a collaboration to establish a joint laboratory in Cambridge, UK.
Contract Research & Services > Contract Research > News

Contract Services

MacroGenics, Takeda partner to develop four additional dart therapeutics
By PBR Staff Writer
US-based biopharmaceutical firm MacroGenics and Japan-based Takeda Pharmaceutical have entered into a collaboration agreement to develop and commercialize up to four product candidates.
Contract Research & Services > Contract Services > News
Ligand earns milestone payment triggered by EU approval of Merck’s captisol-enabled NOXAFIL
Ligand Pharmaceuticals Incorporated (LGND) has announced that Merck, known as MSD outside the United States and Canada, has received approval for NOXAFIL (posaconazole) 300 mg Concentrate for Solution for Infusion from the European Medicines Agency (EMA).
Contract Research & Services > Contract Services > News